Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts

A Pooled Analysis of Five Randomized Clinical Trials

Marco Roffi, MD; Debabrata Mukherjee, MD; Derek P. Chew, MBBS; Deepak L. Bhatt, MD; Leslie Cho, MD; Mark A. Robbins, MD; Khaled M. Ziada, MD; Danielle M. Brennan, MS; Stephen G. Ellis, MD; Eric J. Topol, MD

Background—Despite widespread use of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors for percutaneous coronary interventions (PCI) of bypass grafts, data supporting this strategy are lacking.

Methods and Results—A pooled analysis of 5 randomized intravenous GP IIb/IIIa inhibitor trials (EPIC, EPILOG, EPISTENT, IMPACT II, and PURSUIT) was performed, and outcomes of graft interventions were assessed at 30 days and 6 months. Compared with PCI of native circulation (n=11005), graft interventions (n=627) were associated with worse outcomes and in particular with a doubling of mortality at 30 days (2.1% versus 1.0%, P<0.006) and 6 months (4.7% versus 2.0%, P<0.001). Revascularization of a graft was identified as an independent predictor of death, myocardial infarction, or revascularization at 6 months (hazard ratio, 1.42; 95% CI, 1.24 to 1.63; P<0.001). Among patients undergoing graft PCI, the incidence of the triple end point at 30 days was 16.5% in the platelet GP IIb/IIIa inhibitor group and 12.6% in the placebo group (odds ratio, 1.38; 95% CI, 0.85 to 2.24; P=0.18). At 6 months, 39.4% of patients randomized to GP IIb/IIIa inhibitors and 32.7% of patients allocated to placebo had an ischemic event (hazard ratio, 1.29; 95% CI, 0.97 to 1.72; P=0.07).

Conclusions—Intravenous platelet GP IIb/IIIa receptor inhibition does not improve outcomes after PCI of bypass grafts. In the absence of mechanical emboli protection, this procedure is associated with high incidence of death and nonfatal ischemic events. (Circulation. 2002;106:3063-3067.)

Key Words: angioplasty • bypass • platelets • glycoproteins • stents

Coronary artery bypass grafting is an effective treatment for patients with advanced coronary artery disease. However, whereas internal mammary artery grafts have excellent long-term patency,1 failure of venous conduits remains a major limitation of surgical revascularization.2,3 Percutaneous coronary intervention (PCI) of bypass grafts is associated with worse outcomes compared with procedures involving the native circulation. Acute complications include distal embolization, no-reflow, and higher rate of periprocedural myocardial infarction (MI).4 Subsequently, patients remain at increased risk of repeat revascularization.5 Clinical trials have consistently demonstrated a benefit from platelet glycoprotein (GP) IIb/IIIa receptor inhibition in patients undergoing PCI.6 However, despite the widespread use, data supporting these agents for bypass graft interventions are lacking. Conversely, mechanical emboli protection has recently proven to be highly effective in this setting, predominantly by reducing the incidence of periprocedural MI.7 To assess the impact of IIb/IIIa integrin blockade on bypass graft interventions, we performed a pooled analysis of 5 randomized GP IIb/IIIa receptor inhibitor trials and addressed the outcomes among patients undergoing PCI of a bypass graft.

See p 2994

Methods

Study Population

The individual data of patients undergoing PCI of a bypass graft within 5 platelet GP IIb/IIIa receptor inhibitor trials (Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications [EPIC], Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade [EPILOG], Evaluation of Platelet IIb/IIIa Inhibitor for STENTing [EPISTENT], Inte-
Eptifibatide 180 μg/kg bolus with a 0.75-μg/kg per minute infusion or placebo for up to 72 hours. Adjunctive unfractionated heparin was encouraged but not required. A proportion of patients underwent PCI and, among those, 166 patients had revascularization of a bypass graft. In the PURSUIT trial,12 2792 patients eligible for coronary stenting with similar entry criteria as in the EPILOG trial were randomized to stent plus placebo, stent plus abciximab, or balloon angioplasty plus abciximab. Patients received abciximab in the same doses as in the EPILOG trial with weight-adjusted heparin to achieve a target ACT of ≥200 seconds for the abciximab group and ≥300 seconds for the placebo group. A total of 82 patients underwent percutaneous revascularization of a graft. In the IMPACT II study,11 4010 patients undergoing elective, urgent, or emergent coronary intervention were assigned 1 of 3 of following treatments: placebo, a bolus of 135 μg/kg eptifibatide followed by an infusion of 0.5 μg/kg per minute for 20 to 24 hours, or 135 μg/kg eptifibatide bolus with a 0.75-μg/kg per minute infusion. Among the patients, 156 had PCI to a bypass graft. In the PURSUIT trial,12 10 948 patients presenting with acute coronary syndromes were randomized to eptifibatide 180 μg/kg bolus and 1.3 μg/kg per minute infusion or bolus and 2.0 μg/kg per minute infusion or placebo for up to 72 hours. Adjunctive unfractionated heparin was encouraged but not required. A proportion of patients underwent PCI, and among those, 166 patients had revascularization of a bypass graft. In patients undergoing early percutaneous intervention, the drug was continued for at least 24 hours.

### End Points and Statistical Analysis

Baseline characteristics were summarized by the use of frequencies and percentages for categorical factors with χ² tests and means and standard deviations (SDs) for continuous factors with Wilcoxon rank-sum tests. Logistic regression was performed for 30-day death, MI, or urgent revascularization. The 30-day results were reported as odds ratio (OR) and 95% confidence intervals (CI). Heterogeneity of ORs across the trials was tested with the Breslow-Day statistic. Cox proportional hazards models were used to assess 6-month death, MI, or revascularization and 1-year death and death, MI, or revascularization. The results were reported as hazards ratio (HR) and 95% CI. Covariates evaluated in each of the models included age, sex, cardiovascular risk factors (eg, diabetes, hypertension, hyperlipidemia, or smoking), cardiovascular history (eg, peripheral vascular disease, unstable angina, MI, heart failure, or revascularization), clinical presentation (eg, heart rate, blood pressure, or creatinine), platelet GP Ib/IIa inhibitor use, stenting, and cardiac medications at discharge (eg, aspirin, ACE-inhibitors, β-blockers, or statins). Time to event rates was assessed with Kaplan-Meier methods. With respect to stenting, patients who underwent unplanned (bailout) stenting were followed as part of the angioplasty group. The definition of MI was creatinine kinase (CK)-MB greater than 3 times upper limit of normal or new Q waves in 2 contiguous ECG leads in the EPIC, EPILOG, EPISTENT, and IMPACT II trials. In the PURSUIT trial, MI was defined as any CK-MB elevation or new Q waves in 2 contiguous leads. Bleedings events were classified as major or minor according to the criteria used by the Thrombolysis in Myocardial Infarction Study Group.13 The age of the grafts was derived from the last aortocoronary bypass surgery.
1.11 to 1.79; \(P=0.006\) and at 6 months (HR 1.42; 95% CI, 1.24 to 1.63; \(P<0.001\)) within the overall PCI population.

Treatment assignment and complete follow-up data were available for 605 patients (96.5%) undergoing bypass graft intervention. Among them, 389 patients were randomized to IIb/IIIa integrin blockade (abciximab in 51% of cases and eptifibatide in 49% of cases) and 216 patients were allocated to placebo. The two groups were well matched for baseline characteristics (Table 3). The prevalence of history of heart failure was higher in the GP IIb/IIIa group, whereas patients allocated to placebo more frequently had history of unstable angina. The event rates of individual and combined end points in the 2 groups were comparable at 30 days and 6 months (Table 4). The incidence of death, myocardial infarction (MI), or urgent revascularization at 30 days was 16.5% among patients allocated to GP IIb/IIIa inhibitors and 12.6% among those receiving placebo (OR 1.38; 95% CI, 0.85 to 2.24; \(P=0.18\)). At 6 months, the combined event rate of death, MI, or revascularization was 39.4% and 32.7% (HR 1.29; 95% CI, 0.97 to 1.72; \(P=0.07\), respectively (Figure 2). The lack of benefit was consistent across the trials (Figure 3).

Conversely, within the overall PCI population (native and graft interventions), platelet GP IIb/IIIa receptor inhibition was associated with a reduction in death, MI, or revascularization at 6 months (HR 0.89; 95% CI, 0.83 to 0.95; \(P<0.001\)). The incidence of major bleeding was 6.8% among graft PCI patients randomized to platelet GP IIb/IIIa inhibitors and 1.4% among those allocated to placebo (\(P<0.004\)). The corresponding incidences of minor bleeding were 14.9% versus 8.1% (\(P<0.016\)) and of stroke were 0.8% versus 0.9% (\(P=1.0\)), respectively.

The stenting rate was 20% in the GP IIb/IIIa group and 36% in the placebo group (\(P<0.001\)). No difference in outcomes was observed among patients undergoing graft interventions treated with stenting or angioplasty. The com-

![Figure 1. Kaplan-Meier curves for 6-month mortality among patients undergoing PCI of the native circulation and of bypass grafts.](https://example.com/figure1)

![Figure 2. Kaplan-Meier curves for 6-month death, MI, or revascularization among patients undergoing percutaneous revascularization of a bypass graft according to treatment assignment.](https://example.com/figure2)

### TABLE 3. Baseline Characteristics and Discharge Medications According to Randomized Treatment Among Patients Undergoing Graft Interventions

<table>
<thead>
<tr>
<th></th>
<th>GP IIb/IIa (n=389)</th>
<th>Placebo (n=216)</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y, mean±SD</td>
<td>65±9</td>
<td>64±10</td>
<td>0.43</td>
</tr>
<tr>
<td>Male sex, %</td>
<td>82</td>
<td>78</td>
<td>0.27</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>31</td>
<td>30</td>
<td>0.83</td>
</tr>
<tr>
<td>Hyperlipidemia, %</td>
<td>63</td>
<td>66</td>
<td>0.55</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>63</td>
<td>62</td>
<td>0.87</td>
</tr>
<tr>
<td>Smoking, %</td>
<td>18</td>
<td>21</td>
<td>0.34</td>
</tr>
<tr>
<td>History of stroke, %</td>
<td>5</td>
<td>2</td>
<td>0.09</td>
</tr>
<tr>
<td>History of heart failure, %</td>
<td>15</td>
<td>6</td>
<td>0.002</td>
</tr>
<tr>
<td>History of peripheral vascular disease, %</td>
<td>19</td>
<td>15</td>
<td>0.13</td>
</tr>
<tr>
<td>History of MI, %</td>
<td>62</td>
<td>55</td>
<td>0.12</td>
</tr>
<tr>
<td>History of unstable angina, %</td>
<td>70</td>
<td>78</td>
<td>0.048</td>
</tr>
<tr>
<td>Age of bypass grafts, y, mean±SD</td>
<td>7.8±5.0</td>
<td>6.8±4.8</td>
<td>0.09</td>
</tr>
<tr>
<td>Discharge medications, %</td>
<td>Aspirin</td>
<td>90</td>
<td>92</td>
</tr>
<tr>
<td>β-Blockers</td>
<td>55</td>
<td>57</td>
<td>0.72</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>25</td>
<td>23</td>
<td>0.78</td>
</tr>
<tr>
<td>Lipid lowering</td>
<td>43</td>
<td>51</td>
<td>0.11</td>
</tr>
</tbody>
</table>

Smoking defined as current or quit within 1 year.
The main finding of this study, involving a large number of patients randomized to either IIb/IIIa integrin blockade or placebo, is that these agents do not improve the outcome in bypass graft interventions. Accordingly, no benefit from IIb/IIIa integrin blockade was detected in terms of individual or combined end points either at 30 days or at 6 months. The lack of efficacy was consistent across the trials in the absence of heterogeneity (Breslow-Day $P=0.51$ for 30-day death, MI, or urgent revascularization). This result was in striking opposition to the significant benefit derived from these agents in the overall PCI population (native and graft interventions). From a safety perspective, adjunctive GP IIb/IIIa receptor inhibition was associated with an increased incidence of major and minor bleedings. Data from the initial abciximab experience had suggested that IIb/IIIa integrin blockade might be helpful as adjunctive treatment for PCI of bypass grafts. A reduction of distal embolization among patients randomized to abciximab was described in the EPIC trial, although no overall clinical event rate reduction was observed. However, a subsequent pooled analysis of the EPIC and EPILOG trials showed that abciximab reduced early adverse ischemic events after PCI across the whole spectrum of coronary lesion morphology, with only the exception of degenerated vein grafts.

In addition, a single-center series of 243 patients undergoing PCI of a vein graft showed no benefit from abciximab. Our analysis expands the results of these smaller studies to >600 randomized patients and confirms the lack of efficacy derived from IIb/IIIa integrin blockade in this setting.

The pathogenesis of vein graft disease is a complex interaction between thrombosis, intimal hyperplasia, and atherosclerosis. The soft and friable nature of the plaque, characteristic of vein graft disease, translates into a high risk of distal embolization at the time of PCI. Microvascular obstruction secondary to particle migration is believed to be a major source of periprocedural complications associated with percutaneous revascularization of bypass grafts, such as reduced antegrade flow and MI. A recent study, performed on a small group of patients, demonstrated that using an emboli protection filter device, plaque debris could be retrieved in all of the interventions performed, both in the native circulation and in vein grafts. In our analysis, patients undergoing PCI of a graft had an almost 2-fold increase in MI at 30 days compared with those treated for native disease. The likely explanation for the lack of efficacy associated with adjunctive IIb/IIIa integrin blockade is that the amount or the composition of the material embolized during PCI of bypass graft lesions may overwhelm the capacity of these agents to protect the distal vasculature.

Conversely, a strategy based on mechanical emboli protection has been shown to be highly effective in bypass graft interventions. A recent randomized trial of 801 patients demonstrated a 42% relative risk reduction of major adverse cardiac events at 1 month among patients allocated to emboli protection. Most of the benefit was attributable to a reduction in periprocedural MI. Additional studies are needed to define whether the use of platelet GP IIb/IIIa receptor inhibitors in conjunction with emboli protection devices may improve outcomes. Potentially, profound platelet inhibition may have complementary beneficial effects to mechanical protection, in particular when associated with filter devices. Accordingly, whereas the filter offers mechanical protection from larger particle, GP IIb/IIIa inhibitors could exert their beneficial effect on the microvasculature jeopardized from microparticles that escape the filters. In addition, the use of potent platelet inhibition may allow for reduced filter pore size by preventing filter thrombosis, thereby increasing filter efficiency.

Importantly, this analysis demonstrates that more than half of the ischemic events among patients undergoing PCI of a graft occur beyond 30 days. In particular, 1 of 4 patients requires repeat revascularization within 6 months. Therefore, additional strategies are needed to achieve long-term benefits.
Although we did not detect a benefit from stents among patients undergoing a bypass graft intervention, no conclusion can be derived from these data, because stenting was not randomly assigned in some of the trials. The benefit of stenting among patients undergoing PCI of a vein graft has been shown in a small randomized trial and in a recent single-center series.17

Limitations

Inherent to all pooled analyses, the included trials differed in design, inclusion criteria, therapeutic agents, and regimens, among other variables. However, the Breslow-Day test, which examines the statistical heterogeneity among ORs and therefore provides information about the validity of pooling the results from different trials, failed to demonstrate significant diversity among the analyses. The dose of eptifibatide used in the IMPACT II and PURSUIT trials was lower than the one presently recommended, potentially reducing the efficacy of the drug. Nevertheless, the lack of benefit was observed across the trials and was in opposition to the advantage derived in the overall PCI population. In addition, the 2 eptifibatide trials did not differentiate between arterial and venous graft interventions. Therefore, all graft interventions were included in the present analysis. However, most graft interventions likely involved vein grafts. Accordingly, in the EPIC, EPILOG, and EPISTENT trials, where graft type was tracked, 93% of all graft PCIs were performed on vein grafts. Finally, we addressed any revascularization at 6 months and not the more specific target vessel revascularization, because the latter was not assessed in the PURSUIT trial.

Conclusions

This pooled analysis, including a large randomized experience on intravenous platelet GP IIb/IIIa receptor inhibitor as adjunctive treatment for bypass graft interventions, demonstrates that IIb/IIIa integrin blockade does not confer benefit in this setting. In the absence of mechanical emboli protection, bypass graft interventions are associated with a significantly higher incidence of death and nonfatal ischemic events compared with procedures involving the native circulation.

Acknowledgments

Dr. Roffi was supported by a research grant of the Swiss National Science Foundation. The authors acknowledge Donna Bressan and Suzanne Turner, The Cleveland Clinic Foundation, for editorial assistance and graphic support.

References

Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts: A Pooled Analysis of Five Randomized Clinical Trials
Marco Roffi, Debabrata Mukherjee, Derek P. Chew, Deepak L. Bhatt, Leslie Cho, Mark A. Robbins, Khaled M. Ziada, Danielle M. Brennan, Stephen G. Ellis and Eric J. Topol

_Circulation_. 2002;106:3063-3067; originally published online November 18, 2002; doi: 10.1161/01.CIR.0000041250.89627.A9

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/106/24/3063

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/